Loading stock data…
Unicycive Therapeutics, Inc. (UNCY)
$5.03-0.13 (-2.52%)
Market ClosedLast close Sep 8
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Unicycive Therapeutics, Inc. in the Healthcare sector is trading at $5.03 with a market capitalization of $192M. Wall Street consensus targets $28.22 (9 analysts), implying a +461.1% move over the next 12 months. The stock is currently 42% below its 52-week high of $8.74, remaining 21.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +461.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.44M↓ | -$7.22M↑ | -$7.34M↓ | -$6.96M↑ | -$7.99M |
| Net Income | -$12.82M↑ | -$14.67M↓ | -$6.01M↑ | -$6.45M↓ | $570,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate bindin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$192.24M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-105.95%
Volume
Today's trading volume
784,439
Recent News
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) shares gained 2.
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
In late June 2026, Unicycive Therapeutics received a Complete Response Letter from the FDA on its resubmitted oxylanthanum carbonate NDA, citing unresolved third-party manufacturing deficiencies while raising no new clinical efficacy or safety concerns and requesting no additional data. This outcome highlights how a late-stage drug’s progress can hinge on an external manufacturer’s compliance status even as labeling talks with regulators continue. We’ll now examine how the FDA’s focus on...
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval
Unicycive Therapeutics said on Tuesday that the U.S. Food and Drug Administration has again refused to approve its drug oxylanthanum carbonate.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9%
Top Midday Decliners
Unicycive Therapeutics (UNCY) said Tuesday it has received a Complete Response Letter from the US Fo